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Intracellular Iron Concentration 
and Distribution Have Multiple 
Effects on Cell Cycle Events
Paul Seligman and Gamini Siriwardana
Abstract
Iron is essential for numerous cellular reactions that require oxygen transfer. 
Iron deficiency is a common problem in humans and is the most common nutri-
tional disease worldwide. However, excess cellular iron can be toxic. Maintenance 
of iron hemostasis utilizes specialized pathways responsible for iron transport, 
iron uptake by cells, and appropriate cellular distribution of iron for utilization or 
storage. This chapter reviews how iron depletion is associated with inhibition of 
cellular proliferation and cell cycle arrest at different parts of the cell cycle. These 
effects are based on the effective chelation of iron, and more importantly on dif-
ferences in various tissue responses to both iron depletion and iron toxicity. These 
differences may explain why in some tissues, particularly rapidly growing cancer 
cells, iron depletion causes cell cycle arrest and apoptosis, a form of programed cell 
death. Other neoplastic tissues are more prone to the toxic effects of iron, which 
can induce autophagic cell death (termed ferroptosis) via reactive oxygen species 
resulting in lysosomal degradation of cellular constituents. An appreciation of 
these differences can be utilized by novel pharmaceutical agents discussed below 
designed to treat specific cancers.
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1. Introduction
Iron is mainly used in oxygen transfer reactions necessary for moving oxygen to 
tissues by heme moieties including hemoglobin and myoglobin, enzymes necessary 
for oxidative phosphorylation, and oxygen transfer reactions by enzymes contain-
ing iron sulfur compounds [1, 2]. Compared to other essential micronutrients, 
iron is found in relatively high (micromolar) concentrations in tissues and serum. 
Although essential for these oxygen transfer reactions, excess iron is toxic [1–4]. 
Therefore complex pathways have evolved to maintain proper iron hemostasis 
utilizing specialized proteins responsible for iron transport, iron uptake by cells, 
and appropriate cellular distribution of iron for utilization or storage [1–2]. Based 
on iron needs, promoters control transcription of proteins involved in iron homeo-
stasis. Additionally, specialized elements regulate mRNA translation called iron 
regulatory elements act in a coordinated manner to rapidly regulate concentrations 
of transferrin receptor (necessary for transferrin bound iron cellular uptake) when 
more iron is needed, and ferritin, (the iron storage protein) when the cellular iron 
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concentration is high [1, 4]. Ferritin concentrations both intracellular, and small 
amounts of secreted ferritin found in serum, are increased when there is excess 
iron, as well as in inflammatory conditions such as infections or cancer, presumably 
to inhibit iron utilization as well as protect against cellular iron toxicity. Transferrin 
receptor density is much higher in cells that require more iron, such as cells that 
synthesize hemoglobin and cells that are actively proliferating [5].
Agents that interfere with iron uptake or iron utilization have been used to treat 
cancer. One such agent used in limited clinical studies is gallium, a relatively inert 
metal that binds to transferrin and inhibits cellular iron uptake and utilization 
[6]. Another is the iron chelator deferioxamine (DFO) used in the treatment of 
neuroblastoma [7]. DFO has been considered the “gold standard” as a treatment for 
iron overload [1, 4]. However, newer iron chelators are not only more practical (oral 
gastrointestinal absorption) but have improved iron chelation efficacy and a more 
rapid onset of action. They are also lipophilic, however, and hence can potentially 
confound other biologic processes [8], including lipid peroxidation and autophagy 
if used for iron depletion only. Lipophilicity may have more potential for cancer 
treatment, particularly in combination with carefully chosen chemotherapeutic 
agents [8, 9], since utilizing the iron chelation effect alone combined with agents 
that specifically inhibit DNA synthesis, for example, may result in less combined 
efficacy [10].
Iron, therefore, is a requirement for cellular proliferation, particularly rapidly 
growing cells (including cancer cells). Clinical measurements of iron status in 
epidemiologic studies have shown a lower incidence of cancer in iron depleted 
individuals [11, 12], better survival in patients whose tumors retain less iron, and a 
higher incidence in those with or at risk for iron overload [13, 14].
Cellular iron depletion caused by the use of iron chelators in vitro is associated 
with inhibition of cellular proliferation attributable to cell cycle arrest [15–17]. 
Initially the deficit was ascribed only to inhibition of ribonucleotide reductase 
(RNR) an iron dependent enzyme necessary for DNA synthesis. The iron facilitates 
formation of a tyrosyl free radical at the active site of the M2 protein subunit of 
RNR [18, 19]. Hydroxyurea (HU), a cancer chemotherapy agent well absorbed after 
oral administration, is converted to a free radical nitroxide in vivo and quenches the 
tyrosyl free radical of RNR. Inhibition of RNR is associated with an early S phase 
block (sometimes described as a G1/S block). Some studies have indicated that the 
S phase block associated with ribonucleotide reductase inhibition might be distin-
guished from a G1 block, which may also occur with iron depletion [20, 21].
2.  Iron depletion causes inhibition of cellular proliferation and at least 
two blocks in the cell cycle
More recently, an important advantage for studying cell cycle events has been the 
development of newer reagents that better pinpoints these events. In particular, anti-
bodies that recognize cell cycle specific phosphorylation events, such as kinase activa-
tion status, have proven quite useful. Our more recent studies have shown that the 
two blocks caused by HU vs. iron chelation can be distinguished by different cell cycle 
events. In these studies we utilized neuroblastoma cell lines that are relatively sensi-
tive to growth inhibition by iron depletion [22]. Although several other cell lines have 
shown both G1 and S phase inhibition by iron chelation, we chose the SKNSH neuro-
blastoma line because of reproducible predictable growth rates as well as consistently 
diploid chromosomal makeup and consistent contact inhibition with greater than 90% 
of cells in (G0) G1. SKNSH cells uniformly respond to various stimuli including those 
that promote cell proliferation. Examples of these promoters include simply subculture 
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into serum containing media. These conditions make the cell line particularly useful 
for the study of very early cell cycle events after the stimulus for proliferation.
In these studies, timed experiments used sequential blocking by specific agents 
including aphidicolin (aph) (DNA polymerase inhibitor causing G1/S block), HU 
(RNR inhibition), specific kinase inhibitors (i.e., psrc or pcdk2 inhibition), and 
DFO. Cells were > 90 in G1 phase due to contact inhibition and stimulated to prolif-
erate by subculture in “fresh” medium in 10% fetal calf serum (FCS) Timed studies 
were performed at the time of the proliferation stimulus, the addition of these spe-
cific agents, and “release” (wash out) of these agents. “Release medium” containing 
heat inactivated FCS was added after the attached cells were extensively washed 
with phosphate buffered saline. In previous studies we found that medium such as 
RPMI (supposedly with no added iron salts or FCS) actually contains 1–2 μmol/L 
of contaminating iron salts and about 0.6 μmol iron/L presumably bound to the 
transferrin in fetal calf serum. The initial DFO effect was associated with G1 arrest, 
persistence of cyclin E protein but inhibition of cyclin E/cdk2 complex activity, 
and no measurable cyclin A protein. DFO washout and media replacement resulted 
in the rapid disappearance of cyclin E (Figure 1). The block by aph was associated 
with a slight widening of G1 phase suggesting arrest at G1/S, but more importantly 
cyclin A protein was evident with no discernible cyclin E present. In contrast HU 
treatment exhibited a block in early to mid-S phase. DFO added slightly before 
release from aph showed cell cycle changes similar to HU suggesting that this block 
was due to RNR inhibition (Figure 2). These results were confirmed by studies of a 
unique cell line with a much higher rate of proliferation that consistently was resis-
tant to the G1 effects of iron depletion. It also exhibited persistent cyclin A protein, 
perhaps due to less contact inhibition.
Recent studies have indicated at least one reason for the G1 block is an iron 
requirement for psrc activation. Src is inactive in the absence of iron as dem-
onstrated by both lack of phosphorylation of Y416 (active site) and persistent 
phosphorylation at the inactivating Y527. Progression of mammalian cells into S 
phase from late G1 also requires the activation of cdk2 by cyclin E. Cdk2 bound to 
P27 is in an inactive state. In our studies, although the rapid activation of src with 
iron repletion was short-lived, it was rapidly followed by P27 degradation allowing 
Figure 1. 
This figure and legend were taken from Siriwardana and Seligman [23]. Cyclin E levels decrease after 1 h of 
release from the DFO block. Confluent neuroblastoma cells were serum starved for 24 h then split and plated 
into media, one set with DFO (lanes 3–6, 9–12) and one with no DFO (lanes 1–2, 7–8) and were incubated 
for 24 h. After 24 h, one set of cells that was in DFO was replaced with CM (release). Medium in the others 
were replaced with CM (continuously in medium without DFO). The medium in all plates was aspirated 1 h 
later and the cells were lysed using 200 μL of hot SDS loading buffer. Forty microliter samples of the lysate were 
separated by 10% SDS-PAGE and the proteins were transferred to PVDF membranes. This was first probed 
for cyclin E. Then the membrane was stripped and was probed for β-actin. All treatments were conducted in 
duplicate.
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for activation of cdk2 by its phosphorylation at THR 160 presumably resulting in 
activation of the cdk2/cyclin E complex (Figures 3–5).
These events in turn were followed by rapid disappearance of cyclin E protein, 
presumably due to cdk2/cyclin E complex activity, and appearance of cyclin A 
protein allowing cells to proceed into and through S phase. Inhibition of src kinase 
activity may account for decreased downstream events ascribed to iron depletion in 
other cell lines including inhibition of cyclin D synthesis [25], an event not seen in 
SKNSH due to constitutive expression of cyclin D [23]. For example, we have found 
that the S phase kinase associated protein (Skp2), which is responsible for promoting 
p27 degradation, was not upregulated in the presence of DFO [26]. In contrast, p27 
was not degraded after release from the iron block in the presence of the proteasome 
inhibitor MG132 (unpublished data). Other studies have asserted lack of p27 deg-
radation does not allow for activation of cdk2, but more recently iron chelation was 
found to cause specific inactivation of cdk2 by persistence of the p21 inhibitor [27].
Figure 2. 
This figure and legend was adapted from Siriwardana and Seligman [23]. Cyclin A is absent in DFO-treated 
neuroblastoma cells but occurs in cells arrested with aphidicolin or hydroxyurea. Serum starved neuroblastoma 
cells for 24 h were subcultured in CM (FCS), or RPMI/10% FCS with hydroxyurea, aphidicolin or DFO. The 
dishes were incubated for 24 h and the cells were harvested in 0.5 mL of cold PBS, a 50 μL portion of cells 
was used for FACS and the rest were centrifuged, supernatant removed and added with 200 μL of hot SDS 
loading buffer. Forty microliter samples of the lysate were separated by 10% SDS-PAGE and the proteins were 
transferred to PVDF membranes. This was probed for cyclin A. Then, the membrane was stripped and was 
probed for β-actin. All treatments were conducted in duplicate.
Figure 3. 
This figure and legend were adapted from Siriwardana and Seligman [24].Confluent SKNSH cells were 
sub-cultured into RPMI/10% heat-inactivated FCS with 100 μm DFO and incubated. After 20 h the medium 
was replaced with new medium containing no DFO and 10% heat deactivated FCS. The cells were harvested at 
regular intervals beginning 15 min after aspirating the medium and adding hot SDS loading buffer. Westerns 
were performed as described and Src p416 levels were determined. Thereafter, the blot was stripped and probed 
for B Actin. Each treatment was conducted in duplicate. Based on densitometry, pSrc/B-Actin (average of 
duplicates) for RM vs. RM with DFO, respectively. 0 time 0.35 vs. 0.29; 15 min 0.78 vs. 0.28; 30 min 0.55 vs. 0.21; 
60 min 0.31 vs. 0.26.
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In recent unpublished studies we have found evidence that cells blocked at G1/S 
by aphidicolin, a DNA polymerase inhibitor, do not proceed into S phase if the cells 
are depleted of iron. The cells remain in G1/S, a block distinguished from both the 
block in G1 associated with iron depletion alone, as well as the block associated with 
RNR inhibition by iron depletion. Progression of cells into S phase after release from 
aphidicolin is prevented with the use of DFO and not with the src inhibitor, AZD, 
suggesting iron depletion has an additional cell cycle arrest mechanism independent 
of src inhibition by iron depletion causing G1 arrest as well as the later arrest due to 
inhibition of RNR caused by iron depletion (similar to the HU arrest),
Cells were incubated in aph or HU in RPMI with 10% F CS for 24 h. Then the 
cells received either no addition, DFO, or AZD for 16 h ahead of release from aph or 
HU. This 16 h time point was chosen because our previous studies have shown that 
DFO required at least several hours to effectively remove the “chelatable” cellular iron, 
a reference to iron that is readily bioavailable, as opposed to, for example, iron stored 
in ferritin. At 16 h (a total of about 40 h) these time periods were chosen because of 
extensive studies detailing the rate of proliferation of SKNSH cells with or without 
added agents, to ensure <10% of the cells are dead (by trypan blue exclusion), and 
allow time for the vast majority of cells to exhibit the block desired, including allowing 
a minority of the cells to “recycle” after division to the area of the block. The cells were 
released from aph or HU to medium, RPMI (10%FCS) with no addition, with DFO or 
with AZD. The cells were harvested 6 h later and a florescent activated cell sorter was 
used in order to measure DNA content utilizing propidium iodide.
Figure 4. 
This figure and legend were adapted from Siriwardana and Seligman [24]. Total p27 levels decrease rapidly 
after release from the DFO block. Confluent SKNSH cells were sub-cultured into RPMI/10% FCS with 100 μm 
DFO and incubated. After 20 h the medium was replaced with new medium as RM. The cells were harvested 
at regular intervals beginning 15 min after aspirating the medium and adding hot SDS loading buffer. Westerns 
were performed as described and (total) p27 levels were determined. Thereafter, the blot was stripped and 
probed for B Actin. Each treatment was conducted in duplicate.
Figure 5. 
This figure and figure legend were adapted from Siriwardana and Seligman [24]. Confluent SKNSH cells 
were sub-cultured into RPMI/10% FCS (CM) with 100 um DFO and incubated. After 20 h the medium was 
replaced with new medium containing no DFO and 10% heat deactivated FCS (RM). The cells were harvested 
at regular intervals beginning at 15 min after RM added, the medium was aspirated and hot SDS loading 
buffer was added. Westerns were performed as described and pcdk2 levels were determined. Thereafter, the blot 
was stripped and probed for total cdk2 and then B Actin. Each treatment was conducted in duplicate.
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Figures 6–10 shows DNA profiles of cells treated as indicated above. Our previ-
ous studies documented that effective chelation of intracellular iron by DFO in vitro 
took at least several hours [20]. Therefore cells incubated in aph for 2 days exhibited 
the expected G1/S block and after adding “release” medium with no addition for 6 h 
cells were almost exclusively in early and mid-S phase (Figures 6 and 7). Aph treat-
ment with DFO added only one half hour before “wash out” [so then is the DFO 
also washed out?], even with the DFO added to the release medium for 6 h, showed 
an almost identical profile as cells without DFO added (Figure 8). However, when 
DFO was added 16 h before release, and the cells were released in medium contain-
ing DFO for 6 h the profile showed cells still arrested in G1/S (Figures 9 and 10).
This effect of iron chelation by DFO causing a block at G1/S is distinct from 
inhibition of src kinase by DFO treatment in G1 phase. Treatment with the specific 
src kinase inhibitor AZD 0530 (AZD) showed almost identical DNA profile results 
as DFO treatment during G1 phase [24]. When AZD was added to cells 16 h before 
release from Aph and continued in release medium (no addition), 6 h later the 
profile showed results similar to no AZD treatment with the vast majority of cells in 
S phase (Figures 11 and 12).
Cells in HU for 48 h at the time of release into fresh medium are in early S phase, 
indicating inhibition of DNA synthesis caused by depletion of deoxyribonucleo-
tides due to inhibition of RNR. These cells will proceed through S phase 6 h later 
after wash out (Figures 13 and 14). However, when DFO is added to the HU con-
taining media 16 h before release most of the cells appear to be in G1/S phase, at the 
time of release. Moreover, when the same cells are released into medium containing 
DFO, the vast majority have still have not entered S phase 6 h later, although there 
are still a few cells in early S.
Studies using inhibitors of cdk2 activity were performed to determine its 
requirement for cell cycle progression. We hypothesized that iron depletion caused 
by DFO at G1 and S phase was not an effect of RNR inhibition, but a different 
process necessary to exit G1/S phase. We therefore assessed the effects of two cdk2 
inhibitors JNJ7706621 (JNJ) and BMS 387032 (BMS). Both inhibitors affect the 
activity of other cyclin dependent kinases but have some specificity for cdk2. These 
agents have been used in humans as investigational study drugs in cancer protocols 
(supported by Johnson and Johnson and Bristol Myers Squibb respectively).
Figure 6. 
Aph at time of release.
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As expected adding both inhibitors to cells treated with aph overnight, and 
maintaining their presence upon aph release (6 h) showed persistent G1/S phase 
arrest (Figures 15 and 16). Moreover, when BMS [28] was added to HU treated cells 
overnight and maintained after release, about 85% of cells remained in G1/S. The 
percentage of cells in S and G2/M phase when JNJ was added under these conditions 
showed about 20–25% of cells in S and G2/M phase, perhaps showing a different 
effect of BMS under these conditions (data not shown).
In conclusion the studies shown in Figures 6–16 indicate there is a third cell 
cycle block caused by iron depletion distinct from the G1 block associated with psrc 
inhibition and the early to mid—S phase block caused by inhibition of RNR. The 
third putative block similar to the G1/S block seen with DNA polymerase inhibition 
(Aph) and with the less specific cdk2 inhibitors (Figure 17).
Figure 7. 
Six hours after release into medium (no addition).
Figure 8. 
Aph 6 h after release with DFO in release medium but no DFO added before.
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In initial Western blot experiments we found that DFO reduces the active cdk2 
and cyclin A, whereas src inhibition does not. Cells were incubated in aph for 24 h, 
followed by addition of DFO for 16 h. Cells treated with aph had measurable src 
kinase, cdk2 kinase and cyclin A protein as shown in our prior studies. As expected, 
cells treated with AZD showed decreased src kinase activity in both incubation 
times but adequate levels of cyclin A and cdk2 kinase. Taken together these results 
strongly suggest that another block caused by iron depletion is associated with 
an event that occurs after src kinase activity, but before the initiation of DNA 
synthesis.
However, further studies need to be performed to assess the significance and 
longer-term effects of the decreased cyclin A and pcdk2 with the longer DFO 
Figure 9. 
Aph at time of release with DFO added for 16 h before rebase.
Figure 10. 
Six hours after release from aph and DFO with DFO in release medium. [G1-88%, S-5%, G2/M-5% “dead” 
cells in this case are shown mostly to the left of the G1 peak and are discounted].
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incubation. These further studies may provide evidence as to why the longer iron 
depletion affects synthesis of cell cycle related proteins. These studies should 
initially put an emphasis on inhibition of promoters (i.e., E2F isoforms, or NFR2, 
etc., see below).
2.1 Selected iron associated cell death and the oxidative state
Until 10 years ago programed cell death with a specific DNA “ladder” measured 
on gels, particularly in cancer cells, was ascribed to a process called apoptosis [29, 30]. 
Evidence for apoptosis was often used to validate anti-neoplastic agents studied 
in vitro. Further studies later showed that apoptosis associated with cells treated 
with cancer chemotherapeutic agents, or a normal process such as depletion of 
Figure 11. 
Aph time of release with AZD added 16 h before release.
Figure 12. 
Aph 6 h after release with AZD in release medium.
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specific antibody producing B cells, apoptosis was mainly described as a caspase-
dependent process [31]. Recently, several non-apoptotic regulated processes that 
result in cell death have been discovered [32]. One of these processes has been 
termed ferroptosis [32]. Ferroptosis is best described as autophagy that results in 
cell death, or autophagic cell death [32]. Overall this process is a combination of the 
cell’s response to toxicity including but not limited to cancer chemotherapy. When 
first described, autophagy was deemed a cell’s response to toxicity including any 
toxin, chemotherapeutic insult or even hypoxia [33, 34]. The process was associ-
ated with lysosomal degradation of cellular constituents including some organelles 
[33, 34]. The initiation of autophagy is not thought to be cell cycle specific. Until 
recently, it was thought to be primarily a protective mechanism by which cells 
Figure 13. 
HU at time of release.
Figure 14. 
Six hours after release in medium with no addition.
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entered senescence, (arrested in G0/G1 phase), presumably before “start” [35]. 
This autophagic process was seldom thought to be a cause of cell death. Some have 
hypothesized that when cancer cells enter senescence a subset become cancer 
initiating cells, or cancer stem cells resulting in re-emergence of a cancer thought to 
be in remission [35–37].
Studies have also indicated that senescence associated reprogramming promotes 
cancer “stemness” that is enriched in relapse tumors [38], resulting in highly aggres-
sive growth potential after escape from G0/G1 cell cycle blockade [38]. Ferroptosis 
was first described in cancer cells with activation of a common oncogene called RAS 
[39]. Inappropriate Ras activity results in autonomous cell proliferation. An inhibitor 
of cell proliferation activated by unregulated RAS was a small molecule called erastin 
[32, 40]. Erastin was found to increase processes associated with autophagy. By some 
Figure 15. 
Aph at time of release with JNJ. JNJ added before release.
Figure 16. 
Six hours after release continued in release medium (no aph).
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accounts [41] increased cellular iron with associated increased reactive oxygen spe-
cies (ROS) contributed to lipid peroxidation resulting in cell death, thus fulfilling the 
diagnosis of ferroptosis. In certain instances initiation of this process can influence 
some neoplastic cells to become more sensitive to chemotherapy [42, 43]. The pro-
cess may also be accelerated by a decrease in ferroportin [44], the only protein that 
promotes cellular iron efflux, resulting in a net increase in cellular bioavailable iron 
[45]. Therefore, the use of passive iron chelation (such as DFO) may actually protect 
certain proliferating cells from autophagy during cell cycle arrest. This process may 
be of benefit for normal cells during proliferation [46, 47], but disadvantageous for 
certain cancer cells during treatment.
Although the precise definition of ferroptosis requires evidence for autophagic 
cell death, in some instances apoptosis may also be part of the process [48]. Some 
studies suggest lysosomal leak degrades ferritin, releasing ferritin iron that stimu-
lates lipid peroxidation and is associated with changes of autophagy that can lead 
to cell death [49]. More recently, p53 has been identified as a ferroptosis inducer 
by inhibiting cystine uptake, decreasing the cells ability to counteract oxidative 
processes possibly via decreased GSH, resulting in increased cellular ROS and 
sensitivity to ferroptosis. Less reducing potential, such as erastin’s mechanism of 
action, was thought to be the main cause of differences in the oxidative state among 
cell types, but iron concentration and/or iron distribution also plays a part. The p53 
effect is thought to be metabolic in nature and not directly related to p53 effects on 
cell cycle, but it has stimulated interest in novel anticancer agents [50, 51]. It is quite 
possible that more efficient lipid soluble iron chelators may be more effective in 
Figure 17. 
Simplified cell cycle figure to illustrate steps that require iron. Progression to the next phase requires activation 
of specific cyclin dependent kinases that depend on binding to each phase specific cyclin(s). X-mid G1 block at 
least partially caused by iron requirement for psrc activation, Y-putative G1/S block that occurs before DNA 
synthesis, Z-S phase block at least partly caused by inhibition of RNR. Based on implicating different promoters 
or changes in the redox state it is quite possible, an iron requirement is necessary in allowing completion of the 
cell cycle.
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promoting cell death from autophagy due to processes associated with ferroptosis 
such as lipid peroxidation.
For example, a recent study has shown that polyamines via several pathways 
are involved with cancer cell proliferation, and these polyamine pathways are 
stimulated by iron. Thus, specific iron chelation not only inhibits cell growth by 
mechanisms detailed above, but also inhibits the cellular proliferation caused by 
the stimulating effect of activated polyamines [52]. Another study has shown that 
increasing levels of the CDK inhibitor p21 are associated with iron chelation [27], 
which can have variable effects on inhibition of cell growth depending on the type 
of chelator as well as the cell type [53]. The study that emphasizes some of these 
concepts, from the laboratory of DR Richardson, involves “targeting” oncogenic 
nuclear factor kappa B signaling [54] with redox-active agents. Under normal 
conditions nuclear factor kappa B signaling occurs under different immunologic 
conditions [55]. However, aberrant activation of this pathway results in tumori-
genesis and unregulated cancer cell proliferation. A hypothesis advanced is the 
use of lipophilic thiosemicarbazone chelators, first studied extensively in 2006 as 
having potent antitumor activity, that could potentially overcome resistance to 
chemotherapeutics [56]. The new studies [54, 57] detail that thiosemicarbazones 
“form redox-active metal complexes that generate high ROS levels.” It is explained 
that nuclear factor kappa B signaling is actually activated when ROS is in sub-lethal 
amounts. However, higher ROS generation will inhibit this signaling as one adjunct 
toward cancer cell death, as opposed to lower ROS generation leading to autophagy, 
leading to cellular senescence with resistance to anticancer therapy and possible 
tumor progression. Cell death (ferroptosis) as opposed to autophagic senescence 
can depend on the tissue type, the redox state, the dose of the lipophilic chelator 
used and the amount of bioavailable iron.
In recent studies now in press we found that in genomic studies of acute myelog-
enous leukemia (AML) patients that had low ferroportin message had significantly 
improved survival compared to those in the higher message group. Using AML 
cell lines and AML patient derived cells we confirmed that low ferroportin expres-
sion compared with high expression resulted in greater iron uptake, faster rates of 
proliferation, and more sensitivity to chemotherapy. At least in AML where survival 
is dependent on chemotherapy response higher rates of cellular iron incorporation 
may improve survival [60].
3. Conclusion
Iron deficiency caused by chelation has been shown to inhibit cellular prolifera-
tion, particularly in rapidly growing cancer cells in vitro since the 1970s. Since then, 
iron depletion has been shown to block specific cell cycle processes associated with 
events in G1, S and probably the G1/S phase transition. Clinical studies of iron 
depletion have supported many of these findings, and a few select investigational 
clinical agents that interfere with iron or deplete cells of iron have been utilized in 
cancer chemotherapy studies. Data are presented regarding specific cell cycle events 
associated with iron depletion, and some differences in these events among differ-
ent cell types are described. Passive iron chelation may better pinpoint a step in the 
metabolic or cell proliferation pathways that require iron. Moreover, the concept of 
ferroptosis associated with excess iron causing autophagic cell death has resulted 
in a plethora of studies. These investigations have generated renewed interest in 
lipophilic iron chelators that result in differential iron binding to sub cellular areas 
based on the malignant cell type. The resulting generation of ROS, inhibition of 
oncogenic tumor promoters, and associated autophagic cell death (with a certain 
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of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
extent of apoptosis) suggest these compounds might be useful chemotherapeutic 
agents. In the future, based on differences in neoplastic tissues, a balance between 
inhibiting cell proliferation by iron depletion and cell death associated with excess 
iron will require further study to maximize both events using investigational agents. 
For example, one transcription factor, NRF2, is known for modulating cellular iron 
homeostasis and is thought to decrease ferroportin in macrophages, presumably 
as a way to decrease bioavailable and potentially toxic iron in other cells. However, 
under pathologic conditions, this transcription factor may increase iron retention 
by malignant cells [58]. Hepcidin, a hormone made in the liver, under normal 
conditions is stimulated by inflammation and results in degradation of ferroportin 
in macrophages. This presumably allows for increased storage of iron and lower 
iron in serum [45]. However, more needs to be known about how hepcidin affects 
tumor cells under pathologic conditions [45]. In another example it was found that 
in estrogen receptor positive breast cancer cells, ferroportin message was signifi-
cantly reduced with estrogen treatment. Of further interest, a functional estrogen 
response element was identified within a ferroportin promoter that would repress 
ferroportin expression [59]. Unfortunately, pharmaceutical companies have a 
protective interest in new agents, especially those that have potential in the lucrative 
cancer treatment market. Therefore they are hesitant to publish studies showing 
biologic effects of an agent, particularly if the effect might be construed as leading 
to a potentially toxic event.
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